Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes (2021)

First Author: Garcia-Manero G
Attributed to:  Transcriptional Regulation of GATA-1 funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 33764805

Publication URI:

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 13

ISSN: 0732-183X